929037-30-9Relevant academic research and scientific papers
Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents
Dissoki, Samar,Eshet, Renana,Billauer, Hana,Mishani, Eyal
scheme or table, p. 41 - 52 (2009/12/01)
Inhibition of epidermal growth factor receptor tyrosine kinase (EGFR-TK) has emerged as a major approach for cancer-targeted therapy. Consequently, there has been a great interest in the use of labeled EGFR-TK inhibitors as positron emission tomography (P
POLYALKYLENE GLYCOL DERIVATIVES OF IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE
-
Page/Page column 61; Figure 3, (2010/11/26)
Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK irrevers
